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1. Introduction 
Antiphospholipid syndrome (APS) is a common and very devastating disease. It is an 
autoimmune disease, which differs from most other systemic autoimmune illnesses by its 
propensity to develop thrombosis. APS is defined as the co-occurrence of antiphospholipid 
antibodies (aPL) with the characteristic clinical symptoms. The problem exists on the 
laboratory side of the diagnosis which is important to estimate the risk of further thrombosis 
or pregnancy complications. The diagnosis has to be made based on the presence of aPL, 
which are very complex entities. The main objective of this chapter is to review the methods 
of the aPL determinations and the clinical utility of their presence. The aPL pathogenic 
mechanism will be shortly discussed with an emphasis on the relation between thrombosis 
and inflammation.  
2. The short history of the research in the field of aPL 
APL with the ability to prolong in vitro phospholipid depending coagulation times were 
discovered in 1952 (Conley & Hartmann, 1952) in patients suffering from systemic lupus 
erythematosus (SLE). Only much later, it was discovered that in vivo they do not act as 
anticoagulants (Bowie et al. 1963) and can be found not only in SLE patients but also in 
apparently healthy subjects. The term ”lupus anticoagulant” (LA) was used for the first time 
in 1972 by Feinstein and Rapaport (Feinstein & Rapaport, 1972). In 1980s, it became clear 
that LA belongs to a group of autoantibodies directed against negatively charged 
phospholipids and anticardiolipin antibodies (aCL) were determined for the first time using 
radioimmunoassay (Harris et al., 1983). The presence of aPL was associated with many 
different clinical signs and symptoms. Finally for the first time a definition of APS was 
established in 1987 (Harris, 1987). Then, in the 1990s, antibodies to antiphospholipid protein 
cofactors - beta2 glycoprotein I (a┚2GPI) and prothrombin were discovered (Bevers et al., 
1991; Galli et al., 1990; Mc Neil et al., 1990).  
A set of guidelines for the detection of LA were published in 1991 and 1995 and then revised 
in 2009 (Exner et al., 1991; Brand et al., 1995; Pengo et al., 2009). Similar efforts were started 
from the beginning to standardize enzyme-immunoassays to detect aCL (Pierangeli & Harris, 
2008). In 1999, first changes (e.g. exclusion of thrombocytopenia) were introduced to the 
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definition of APS (Wilson et al., 1999) and then the definition was modified in 2006 (Miyakis 
et al., 2006). Since the last modification a┚2GPI are one of the laboratory criteria of APS. 
3. LA phenomenon – The most clinically relevant aPL 
LA was the first discovered aPL antibody, and until now, it has been known as the most 
clinically relevant. Although sensitive and quantitative ELISA-based methods were 
developed to detect antiphospholipid antibodies, LA detected by coagulometric tests has 
been shown to be more associated with thrombosis (Galli et al., 2003). From the beginning, 
LA together with aCL were included among laboratory criteria of the APS (Harris, 1987).  
The term LA is a double misnomer because these antibodies are present mainly in patients 
without lupus erythematosus and in vivo react as procoagulant (Jamrozik et al., 1993). The 
name “anticoagulant” was given because in vitro in phospholipid-dependent liquid-phase 
assays they prolong these tests acting as anticoagulants.  
The detection of LA is founded on a wide range of clot-based tests and according to the 
guidelines three-step procedure is required. The laboratory diagnosis should be based on 
prolongation of a phospholipid dependent clotting tests, lack of correction of the prolonged 
clotting time by addition of a small amount of normal plasma and correction by the 
presence of the higher concentration of phospholipids. 
The detection of LA is delicate and sometimes impossible when the patient is already 
treated with oral anticoagulants. Pre-analytical variables (e.g. quality of sample collection, 
centrifugation, temperature of storage) strongly influence final results. The specimen is 
sodium citrate anticoagulated blood which requires immediate, quick, double 
centrifugation. If the test is not immediately performed, the sample needs to be frozen in a 
deep freeze. Moreover, one of the extremely important aspects ensuring the good test results 
is the process of the blood collection. The smooth blood flow prevents activation of the 
coagulation processes.  
In the past, many different tests were used in the process of LA detection, e.g.: kaolin 
clotting time (KCT) (Galli et al., 1995), silica clotting time (SCT) (Dragoni et al., 2001), diluted 
prothrombin time (dPT) (Liestøl et al., 2002), activated partial thromboplastin time 
sensitive/insensitive ratio (aPTT ratio) (Ames et al., 2001), Textarin/Ecarin clotting time 
(Triplett et al., 1993). Recently, only two following tests have been recommended for LA 
detection based on practicality and global experience: diluted Russell viper venom time 
(dRVVT) and aPTT. The use of other tests has been discouraged mainly due to the limited 
experience rather than their poor performance (Pengo et al., 2009). Interestingly, according 
to one systematic literature review, the risk of thrombosis appeared to be independent of the 
laboratory tests used for LA identification (Horbach et al., 1996). 
Our clinical research results show a comparable performance of the LA tests based on aPTT 
and dRVVT as recommended by the latest guidelines for LA detection with the other tests 
(Swadzba et al., 2011 a). Our study group that was used consisted of 336 subjects suffering 
from various autoimmune diseases. We used aPTT, dRVVT and dPT tests for LA detection 
together with a ratio between sensitive and insensitive aPTT reagents. All LA tests 
performed were associated with a previous episode of thrombosis (ORs range: 3,5 to 8,4). 
Diluted PT dependent LA showed stronger association with the history of thrombosis than 
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aPTT or dRVVT dependent LAs (OR = 6,0 vs. 5,0 and 4,3 respectively). On the other hand, 
LA based on the ratio between sensitive and insensitive aPTT reagents showed weaker 
association with APS clinical symptoms than other LA tests. 
Furthermore, it has been shown that a┚2GPI are better predictors of thrombotic 
complications than antibodies directed against prothrombin (Swadzba et al., 1997). For this 
reason, various attempts have been made to specifically detect ┚2GPI dependent LAs. Two 
methods of ┚2GPI dependent LA identification were described (Pengo et al., 2004; 
Simmelink et al., 2003). The first studies indicate that the ┚2GPI dependent LAs show 
superior association with thrombotic complications than LAs caused by other antibodies (De 
Laat et al., 2004, 2001). It was confirmed recently in our study (Swadzba et al., 2011 a). The 
highest odds ratio for thrombosis was found for a┚2GPI dependent LA (OR= 8,3; 
specificity/sensitivity=98%/15%). Because of high specificity (98%) but low sensitivity 
(15%) a┚2GPI dependent LA was suggested to be the second line assay to choose the 
patients with the highest risk of thrombosis.  
In the recent guidelines only two tests were selected because if more tests were performed 
the percentage of false positive results could be too high. In our study even only two tests 
were used the odds ratio for both (and/or) was lower than for each one separate test. LA 
tested by aPTT and/or dRVVT (at least one out of two positive tests), as it was 
recommended by the published guidelines, was associated less strongly with the history of 
thrombosis (OR=4,1) than any of these tests separately (OR=5,0 and 4,3 respectively). The 
advantage of the latter (aPTT and/or dRVVt) lies only in their higher sensitivity (45% vs. 
43% for aPTT dependent LA and 32% for dRVVT dependent LA). When both tests were 
positive (“double LA positivity”) the association with thrombosis was stronger (OR=6,5) 
than when only one test was positive. Double LA positivity detected by all tests performed 
was firmly associated with the history of thrombosis.  
We agree with the recommendation, that two tests should be performed and the number of 
positive tests should be given and commented on the final result. The results with two 
positive LA tests could be named as “double LA positive” and possibly point to the patients 
with the highest risk of thrombosis. 
LA detection is troublesome, poorly standardized, and its laboratory accuracy and clinical 
utility varies, igniting a lot of controversies. As a consequence several national and 
international inter-laboratory surveys have shown unacceptable differences in LA test 
results between various participating laboratories (Arnout et al., 1999; Pengo et al., 2007b). 
The rates of false positive and false negative results remained relatively high. In the future 
the differences among laboratories should be less pronounced, because the new guidelines 
gave more strict recommendations about blood collection requirements, choice of the tests, 
mixing studies (1:1 proportion), confirmatory tests, interpretation, expressing and reporting 
the results.  
However there is still a need to conduct more research to answer a lot of questions, e.g.: how 
identify the most clinically relevant LA, how to define the presence of strong LA as opposed 
to the weak ones. From a clinical point of view, any LA results should always be considered 
in the context of a full laboratory aPL profile comprising of aCL and a┚2GPI, because 
isolated LA positivity may be frequently found in subjects without any clinical symptoms 
(Pengo et al., 2007a). 
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4. ACL – The most sensitive aPL test 
ACL were firstly detected by radioimmunoassay but just after ELISA based format replaced 
the former tests (Loizou et al., 1985). It is well known that basic performance of aCL assays 
is determined by various factors including the type of microtiterplate, the source of 
cardiolipin, the solvents, the usage of cofactor (De Groot et al., 2008). There were a lot of 
efforts to standardize the aCL tests (Wong et al., 2005, Wong & Favaloro, 2008). However it 
is not easy because the aCL ELISA does not detect aCL, but antibodies to proteins which 
bind to cardiolipin coated on the surface of microtiterplate. ┚2GPI is present in the 
microtiterplate wells from the patient serum (tested), bovine serum (solvent) or sometimes 
┚2GPI is extra added to aCL tests. ┚2GPI can bind to cardiolipin coated on the plate and later 
a┚2GPI bind to the complex ┚2GPI-cardiolipin. However the cardiolipin on microtiterplate 
can be bound also to prothrombin and other proteins. For this reason an aCL test is not 
purely a┚2GPI test, but, in fact, there are detected antibodies against different proteins which 
bind to anionic phospholipids. This is probably the reason why ELISAs to detect 
anticardiolipin antibodies are more sensitive but less specific tests than a┚2GPI  ELISAs. 
Proper and stable calibrators are very important for conducting aCL tests. Almost since the 
beginning one source of human polyclonal calibrators from patients samples was applied 
(Louisville calibrators) (Harris et al., 1987). These widely used calibrators helped produce 
comparable results between laboratories and introduce international units (GPL and MPL 
units) (Harris, 1990). The Louisville calibrators were used for many years in spite of the 
problems with batch to batch variations (Favaloro & Wong, 2011). Some years ago 
monoclonal antibodies to ┚2GPI became available and they started to be used as the 
calibrators both for ┚2GPI ELISA and aCL ELISA (Ichikawa et al., 1999). Even though a great 
progress has been made, there is no consensus for internationally accepted aCL calibrators.  
The other important issue in aCL testing is associated with choosing an optimal cut-off 
point. In the first studies, the 95th percentile of healthy population was used (Musial et al., 
1997), but from the beginning it was well known that low positive results were less 
important than high positives. In the Sapporo APS criteria, only medium or high titer of aCL 
were considered as serological criterion of APS (Wilson et al., 1999). In the newest, updated 
criteria, aCL are regarded as positive if exceed the 99th percentile or 40 GPL/MPL units 
(Miyakis et al., 2006). There is an inconsistence in offering two different, alternative values 
to identify the presence of aCL in a meaningful, pathological levels (Swadzba et al., 2007). In 
our in-house method the value of the 99th percentile of a normal population corresponded 
to 26 GPL and 27 MPL, respectively. Obviously, the sensitivity was higher for a lower cut-
off value (99th percentile), specificity – for the higher one (above 40 GPL/MPL), but overall, 
relative risk for thrombosis was quite similar (3,71 vs. 3,72) (Swadzba et al., 2007). 
However, until generally accepted international standard is developed, any arbitrarily 
chosen cut-off value will leave doubts about its validity. It seems reasonable to have only 
one threshold value when comparisons between different methods and  laboratories are 
required. In our opinion, the 99th percentile of the healthy population offers by far the better 
threshold value that could be generally accepted (Swadzba & Musial, 2009). 
Nevertheless, one needs to remember that lower levels of both aCL and a┚2GPI can be 
associated with significant (but low) risk of clinical complications (Swadzba et al., 2007). 
Even if it is persistent positivity, one low positive result could be neglected, but when two or 
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more aPL are present in low titer the situation can be different. We can speculate that in the 
recently developed definition of the “triple positivity” maybe even low positive antibodies 
could be enough to register as positive (when at least one kind of antibodies is highly 
positive).  
On the contrary, patients with very high levels of antibodies, especially of the IgG class, are 
at particularly high risk of thrombosis. This has been clearly reflected in our study by a 
group of patients with anticardiolipin antibodies level above 80 GPL/MPL who had the 
highest number of thrombosis in the past (Swadzba et al., 2007). In our opinion, this finding 
requires and calls for an objective, clinically important and uniformly accepted definition of 
“high levels” of aPL. 
It should be emphasized that the class of anticardiolipin antibodies is crucial for 
determining the risk of APS clinical symptoms. It was shown in many studies that IgG class 
of antibodies correlates much better with the history of thrombosis than IgM type (Swadzba 
et al., 2007). It is of concern that the updated criteria do not separate IgG and IgM classes. 
We propose to grouped separately IgG and IgM antibodies and introduce the thrombosis 
risk score in which IgG antibodies will be more important than IgM. Some other authors 
even think that IgM antibodies should be abandoned from the criteria of APS (Galli et al., 
2008).  
The value of IgA antibodies in diagnosis of APS is still uncertain. According to the latest 
guidelines this class of antibodies does not add clinically important information (Miyakis et 
al., 2006). 
5. Anti β2GPI – The most “real” aPL test? 
┚2GPI is a 50-kDA phospholipid binding protein present in plasma in concentrations of 
approximately 200 mcg/ml. The function of ┚2GPI is not clear until now however it was 
regarded as natural anticoagulant. The genetic deficiency of ┚2GPI appears to be not 
involved with any diseases (Matsuura et al., 2010). It has been  found recently that ┚2GPI can 
play an important role in the immunity (De Groot & Meijers, 2011). There is no evidence that 
any of β2GPI polymorphism is connected with the presence a┚2GPI antibodies or APS 
(Swadzba et al., 2006). 
Antibodies against ┚2GPI were discovered in 1990 and it is well documented nowadays that 
┚2GPI is the main important antigen in APS pathophysiology. It was demonstrated that the 
mice injected with ┚2GPI produce aCL as well as a┚2GPI (Gharavi et al. 1992). From the 
pathophysiological point of view, inclusion of ┚2GPI antibodies to existing criteria seems to 
be well-founded. It is generally accepted that domain I of ┚2GPI serves as a major antigen 
for pathological aPL (Ioannou & Rahman, 2010). A┚2GPI IgG antibodies are strongly 
associated with clinical complications of APS. This further justifies inclusion a┚2GPI into the 
APS laboratory classification criteria.  
It is noted, that the presence of a┚2GPI was closely associated with the presence of other 
aPL. For this reason, addition of a┚2GPI to the diagnostic armamentarium changed only 
slightly the risk prediction of clinical complications based on the presence of LA and aCL. In 
our study their inclusion added 5 extra patients diagnosed with APS, who otherwise would 
be missed (less than 5% of the APS population) (Swadzba et al., 2007). Overall, the addition 
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of a┚2GPI to the classification criteria might slightly limit the number of the so-called 
“seronegative APS” patients; a relatively small group of subjects with very suggestive 
clinical features and negative LA and/or aCL determinations.  
A┚2GPI, especially of the IgG class, appeared in our patients less frequently than aCL 
(Swadzba et al., 2007). For this reason, being more specific, they showed quite low 
sensitivity, as it was already reported by others (Favaloro & Wong, 2011). Overall odds 
ratios for thrombosis and pregnancy loss is similar to the aCL ones.  
The proposed single method of establishing an upper limit of normal values for a┚2GPI 
introduced by the updated APS criteria would certainly help to compare results between 
laboratories. The choice of 99th percentile as a suggested cut-off value seems valid and very 
well-supported. For example in our research studies, patients tested positive for a┚2GPI 
based on a cut-off set at 99th percentile were at a higher relative risk for thrombosis than 
those considered positive when the cut-off value was set at 95th percentile. However, quite 
low sensitivity of the test (in our study for a┚2GPI IgG – 24%) seems to qualify it rather as a 
risk stratification test or a second test identifying population at the highest risk among APS 
patients (Swadzba et al., 2007). As a screening test or as a test served in a “triple positivity” 
the cut-off value that lies in the 95th percentile may be better and it needs further studies.  
6. Non classical aPL 
The spectrum of autoantibodies associated with APS is likely to extend beyond tests known 
from APS criteria. From the very beginning it was known that cardiolipin is not the only one 
but only one out of the many possible phospholipids served in the tests for detecting aPL. It 
was unlikely that cardiolipin could serve as real antigen for aPL and even that in vivo it is a 
surface for the proteins because cardiolipin is situated only in the inner side of mitochondria 
membranes.  
Other phospholipids were proposed as the antigens. From a pathophysiological point of 
view the phosphatidylserine was very attractive as phospholipid that exists in the cellular 
membranes and flip-flops to the outer side during the cell activation. In fact in our studies, 
the correlation with APS clinical symptoms did not differ between phosphatidylserine 
antibodies and aCL. The correlation between two methods was very high (r=0,8) (Musial et 
al., 2003). Antibodies against other phospholipids were tested less extensively (e.g. 
antibodies against phosphatidylinositol) but similar results were obtained. Due to high cross 
reactivity there was only a little additional clinical information leading to the conclusion that 
there is no need any additional ELISA tests against anionic phospholipids other than aCL. 
The special attention was drawn to antibodies against phosphatidylethanolamine (aPE). 
Phosphatidylethanolamine is a zwitterionic phospholipid normally present in the outer 
leaflet of cell membranes, and it plays a role in reactions of protein C pathway. Antibodies 
can react with the complexes of aPE with high and low molecular weight kininogens 
(HMWK, LMWK), factor XI and prekallikrein (Sugi & McIntyre, 2001). There were some 
studies conducted that show aPE as the only antibody in a limited number of APS patients 
(Karmochkine et al., 1992). 
The method using the mixture of different phospholipids was proposed as an alternative to 
cardiolipin tests and it was called “the real antiphospholipid test”. The concept of the test 
was similar to LA (detecting antibodies against different antigens) and the aPL ELISA from 
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Louisville in some studies showed better sensitivity and specificity than aCL (Pierangeli & 
Harris, 2008). However, most of the studies used cardiolipin as the antigen that was easier to 
standardize and compare between laboratories than tests with different mixtures of different 
antiphospholipids.  
As mentioned early, in 1991 antibodies to the prothrombin (aPT) were discovered (Bevers et 
al., 1991). In the clinical studies aPT were found to be less clinically important than other 
aPL antibodies (Swadzba et al., 1997). However the group of researchers developed a new 
test recognizing clinically relevant aPT. They coated prothrombin on phosphatidylserine 
(PS/PT test) causing new structure configuration of prothrombin. The complex of 
prothrombin and phosphatidylserine is probably showing epitopes which bind clinically 
relevant antibodies. These antibodies rather than antibodies against phrothrombin alone are 
closely associated with APS and LA (Atsumi et al., 2000). 
Test for the presence of anti annexin V antibodies is one of the new tests especially used in 
obstetrical APS. Annexin V plays a significant role as an anticoagulant shield on the surface 
of the trophoblast. In some studies, the presence of anti annexin V antibodies correlates 
positively with a history of pregnancy losses (Iaccarino et al., 2011).  
Anti ┚2GPI - domain I antibodies were tested recently. In contrast to antibodies recognizing 
other domains of ┚2GPI, anti-domain I antibodies are found to be highly associated with 
APS clinical symptoms, however their sensitivity is very low (De Laat & de Groot, 2011).  
7. New trends in aPL determination 
ELISA method is state-of-the-art for aCL and a┚2GPI determination. It is a manual or semi-
manual technology and inter-assay reproducibility is difficult to obtain. Manufacturers put a 
lot of effort to develop new methods. There are some new automated assays for diagnosis of 
the antiphospholipid syndrome on the market (De Moerloose et al., 2010; Persijn et al., 
2011). These assays are two-step immunoassays consisting of paramagnetic particles coated 
with cardiolipin and/or human ┚2GPI. Sensitivity, specificity, agreement and the odds ratios 
when predicting a thrombotic or obstetric event gave comparable results with the ELISA 
methods.  
Western blot is the other technique used recently in aPL determination (Egerer et al., 2011). 
It was published that it gives similar results as ELISA, although the results are only 
qualitative. 
High avidity a┚2GPI was associated with thrombosis and APS, while in the low avidity 
a┚2GPI group non-APS (predominantly SLE) patients prevailed (Cucnik et al., 2011). 
Controversies concerning the role of antibody avidity may be attributed mainly to the 
absence of suitable detection methods. 
We proposed to use ROC (Receiver Operating Curve) methodology to establish 
retrospectively optimal cut-off point for each clinical symptom, each type of the 
antiphospholipid antibodies and to determine the test with the best clinical accuracy (Musial 
et al., 2003). The comparison between tests based on ROC plot analysis is independent of 
any particular threshold values. The calculation of the area under the ROC curve (AUC) 
gives the information about the clinical accuracy. The area of 1,0 means that the test 
perfectly separates subjects with a given APS clinical symptom from those without it (an 
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ideal situation – 100% sensitivity and 100% specificity). When the area is < 0,5 the test does 
not separate such two groups of patients at all. ROC plot analysis is further used to find 
threshold values for aPL which discriminate the best between the patients who experienced 
an APS clinical symptom in the past from those do did not. The optimum the cut-off point is 
the nearest point to the left upper corner on the graph of ROC curve. Such calculated cut-off 
value provides the optimum trade-off between the specificity and sensitivity of the test 
towards a particular clinical symptom.  
8. APS definition and aPL clinical utility 
Classification criteria for the antiphospholipid syndrome were proposed for the first time by 
Harris in 1987 (Harris, 1987). In the definition, he emphasized the co-existence of typical 
clinical complications and laboratory test abnormalities. Among laboratory tests, he listed 
the presence of LA and aCL, which were discovered four years earlier (Harris et al., 1983). 
Typical clinical manifestations included venous and arterial thrombosis, thrombocytopenia 
and obstetrical complications. These criteria were slightly modified during the Conference 
in Sapporo in 1999 (Wilson et al., 1999). Thrombocytopenia was removed as being not 
specific, obstetrical criteria were revised and their very detailed description was given. At 
the beginning of the 1990’s, ┚2GPI was shown to be a major antigen for aPL. For this reason, 
although aCL and a┚2GPI often coexist, a┚2GPI were added to the criteria (Miyakis et al., 
2006). Subsequently, it was shown that a┚2GPI were more specific, but less sensitive than 
aCL as markers of clinical complications of APS. Based on the updated criteria, it is 
recommended to divide patients into classes according to the type and number of antibodies 
present. Patients should be classified into class I when they possess more than one type of 
antibody. In our study, this group did not differ in terms of thrombosis risk from patients 
with the presence of only one type of aPL (Swadzba et al., 2007). Only groups with all three 
types of antibodies (LA + aCL + a┚2GPI) were connected with the higher risk. Class II 
comprises patients with the presence of only one type of antibody (IIa-LA, IIb-aCL and IIc-
a┚2GPI). For thrombosis in general, and especially for venous thrombosis, the presence of 
LA (class IIa) brings the higher risk than groups IIb and IIc (Swadzba et al., 2007). APS 
patients are not routinely connected with the groups because it did not clearly differ by the 
risk of thrombosis or pregnancy loss.  
It was shown that not only the presence of antibodies is important but also the coexistence 
of different antibodies can increase the risk of thrombosis. The term “triple positivity” for 
the presence of all classic aPL was given (Pengo et al., 2010). It is connected with high risk of 
thrombosis. The other high risk factors of APS clinical symptoms have been recently 
discovered: anti domain 1 antibodies, beta2 GPI dependent LA and double positive LA. 
It is concerning, that the updated criteria do not separate IgG from IgM class of antibodies. 
The group of patients with combined: LA and aCL IgG or LA and a┚2GPI IgG, can have 
similar risk of thrombosis as the patients with triple positivity: LA and two IgM antibodies 
(aCL and a┚2GPI). We agree that there is little evidence demonstrating significant 
association between IgM a┚2GPI and aCL but still there are some patients with only high 
IgM positive antibodies and clinical manifestations of APS. It could be too preliminary to 
exclude IgM antibodies completely, so we rather suggest to make a clear distinction between 
antibodies of the IgG and IgM class as the high and low risk antibodies until prospective 
studies remove any doubts that antibodies of the IgM class, even in very high titers bring 
negligible risk of thrombosis.  
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Undoubtedly, laboratory criteria that define the antiphospholipid syndrome require 
modification because the two different possible cut-off values for discrimination between 
positive and negative aCL (>99th percentile and >40 GPL). In 90 aCL-positive APS patients 
it was shown that the values defining 99th percentile of the normal population (17,4 GPL 
and 26,8 MPL) were significantly lower than 40 GPL (Swadzba et al., 2007); this finding was 
already reported by our group about some years earlier (26 GPL and 27 MPL, respectively) 
(Musial et al., 2003). We suggest to change the criteria and start using the 99th percentile as 
the only accepted cut-off value (as for anti-┚2GPI antibodies). Interestingly, Ruffatti (Ruffatti 
et al., 2008) proposed: one criterion to be used for thrombosis (40 GPL) and the other (99th 
percentile) for pregnancy complications. In group of their patients the mean value of aCL 
IgG was higher in thrombosis than in the group with obstetrical complications. It was 
concluded that lower titers can provoke obstetrical complications and are not enough for 
stimulating thrombosis. In our group of patients, the results were quite different. Using 
ROC curves the best cut-off for thrombosis was 17,2 and for recurrent fetal loss slightly 
higher 18,4 (Wu et al., 2008). A certain percentile of healthy population is the objective 
method for determination cut-offs regardless of the test used. It is important because there 
are many debates related to what percentile (i.e., 95th, 97,5th or 99th) is the best to use. This 
is the problem of optimal sensitivity/specificity ratio. The ROC curve methodology can 
show the best cut-off to reach optimum ratio between sensitivity and specificity and the 
highest OR for clinical symptoms connected with positive values of the tests. In 2003 we 
published cut-offs based on ROC curves for different antiphospolipid antibodies. Optimal 
cut-off for aCL IgG was slightly lower than 99th percentile (26 GPL) and far lower than 40 
GPL. We regard it as correct that 99th percentile should be included in the criteria of APS 
but 95th percentile can be used as for a group with doubtful antibodies or in triple positivity 
when two others antibodies are positive. 
Another radical proposition is to abandon aCL determinations completely, which is 
bringing up the argument of high specificity of a┚2GPI for clinical APS symptoms. However 
we should not forget about sensitivity, which is quite low for these antibodies. Also, it has 
not been proven beyond any doubts that aCL antibodies directed against other proteins than 
┚2GPI are with no clinical importance. ACL like LA measure a cocktail of antibodies against 
different proteins and epitopes. From a practical point of view, aCL tests are much cheaper, 
better known by the clinicians and give similarly important clinical information. 
APL positive patients with no APS clinical symptoms are at present excluded from the 
diagnosis of APS syndrome. We agree that the term “syndrome” is connected with any clinical 
symptom. If we agree that “triple positivity” gives high risk for thrombosis even if there were 
no clinical APS symptoms we should consider to develop a new definition. The proposition 
could be aPL dependent thrombophilia. LA and persistently high titers of all groups of aPL 
antibodies in IgG class probably are connected with even higher risk of thrombosis than 
moderate aCL of IgM class in women with one pregnancy loss in the history.  
9. APL – A pathogenic mechanism, the role of inflammation in thrombosis 
The coexistence of aPL and clinical signs of APS is obvious but causative role of aPL is not 
certain. There are some theories how aPL can cause thrombosis or abortions. Most of them 
are connected with prothrombotic and antifibrinolytic mechanisms. Relations between 
thrombosis and inflammation are researched recently. 
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Tumor necrosis factor alpha (TNF-┙) is a cytokine which shares proinflammatory and 
prothrombotic actions, while a soluble form of interleukin-2 receptor (sIL-2R) is considered as 
a typical marker of (auto)immune inflammation with not known direct links to thrombosis. 
The differences in the pathogenesis of APS as compared to other autoimmune diseases might 
be connected with different serum levels of both mediators (Swadzba et al., 2011 b).  
APS was characterized in our study by the highest levels of TNF-┙. Moreover, patients with 
lupus anticoagulant or elevated levels of IgG anticardiolipin or IgG anti-┚2-glycoprotein I 
antibodies had higher TNF-┙ levels than patients without the presence of any type of 
antiphospholipid antibodies. The presence of aPL is associated with higher TNF-┙ level, 
whereas increased level of sIL-2R is rather connected with definite SLE where inflammatory 
processes prevail. It might be hypothesized that TNF-┙ plays a major role in pathogenesis of 
APS thrombotic phenomena. 
In general, systemic inflammation is a potent prothrombotic stimulus. Inflammatory 
mechanisms upregulate procoagulant factors, downregulate natural anticoagulants and 
inhibit fibrinolytic activity (Esmon, 2003). Endotoxin, tumor necrosis factor alpha and 
interleukin-1┙ (IL-1┙) induce tissue factor (TF) expression, primarily on endothelial cells 
and monocytes/macrophages, promoting blood coagulation (Bevilaqua et al., 1986). 
Activation of the complement C5b-C9 complex changes the cell surface to a more 
procoagulant phenotype by the shift of negatively charged phospholipids from the inner to 
the outer membrane (Sims et al., 1988). Inflammatory reaction is also accompanied by the 
increase in fibrinogen and C-reactive protein (CRP) blood levels. CRP itself increases TF and 
decreases TF pathway inhibitor (TFPI) concentrations, what may be important in 
pathogenesis of arterial thrombosis and myocardial infarction (Wu et al., 2008). Of the 
natural anticoagulants, protein C pathway appears to be the most strongly influenced by 
inflammation with thrombomodulin (TM) and the endothelial cell protein C receptor 
(EPCR) being both downregulated by TNF-┙ (Conway & Rosenberg, 1988).  
On the other hand, thrombotic processes enhance inflammatory reactions, mainly through 
the action of TF and thrombin (Chu, 2005). Activation of platelets leads to the release of 
CD40 ligand, which in turn induces TF expression and increases interleukin 6 (IL-6) levels 
(Miller et al., 1993). Thrombin also augments leukocyte adhesion and activation, stimulates 
endothelial cells to produce platelet activating factor (PAF) and increases an expression of P-
selectin (Pierangeli et al., 2001).  
A common inhibitory pathway for thrombosis and inflammation also exists. Activated 
protein C (APC) acting directly as an anticoagulant, functions also as an anti-inflammatory 
and cytoprotective agent through specific receptors: EPCR and protease activated receptor-1 
(PAR-1) (Crawley & Efthymiou, 2008).  
It is possible that TNF-┙ is a proinflammatory cytokine with the strongest prothrombotic 
action. TNF-┙ stimulates monocyte and neutrophil adhesion to endothelium, inhibits 
protein C system, impairs fibrinolysis and increases TF expression on the cell surface 
(Esmon, 2003). Produced mainly by activated monocytes, macrophages, and T lymphocytes, 
this cytokine has been found to be elevated in patients suffering from both SLE (Studnicka-
Benke et al., 1996) and APS (Forastiero et al., 2005). We hypothesized that TNF-┙ might be 
more elevated in APS patients, with thrombosis as its prominent feature, than in those with 
other autoimmune diseases where immune mediated inflammation prevails.  
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10. Conclusion 
In summary, an updated list of APS classification criteria and a revision of LA guidelines 
represent a step forward for better detection of clinically important aPL. However, many 
problems still need to be addressed and an additional research in this field followed by new 
modifications in definitions and criteria seems to be necessary. The important issue is to find 
optimal methods for high risk aPL detection. This may lead to the development of an 
effective primary and secondary prophylaxis of clinical APS complications, which 
constitutes a major goal and challenge for the future.  
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condition connected with thromboses or foetal losses and antiphospholipid antibodies presence. Form that
time there has been a great progress in knowledge, including antiphospholipid antibodies characterisation,
their probable and also possible action, clinical manifestations, laboratory detection and treatment possibilities
. This book provides a wide spectrum of clinical manifestations through Chapters written by well known
researchers and clinicians with a great practical experience in management of diagnostics or treatment of
antiphospholipid antibodies' presence.
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